Genomic

Dataset Information

0

Neoadjuvant Chemotherapy +/- Bevacizumab Pharmacogenomics


ABSTRACT:

Neoadjuvant chemotherapy (NAC) for breast cancer is widely employed. We performed genome-wide association studies (GWAS) to determine if germline genetic variability was associated with benefits, in terms of pathological complete response (pCR), disease-free survival (DFS), and overall survival (OS), in patients entered on the NSABP B-40 NAC (National Surgical Adjuvant Breast and Bowel Project, B-40, Neoadjuvant Chemotherapy) trial where some patients were randomized to receive bevacizumab, in addition to chemotherapy.

PROVIDER: phs001365 | dbGaP |

SECONDARY ACCESSION(S): PRJNA384839PRJNA384840

REPOSITORIES: dbGaP

Dataset's files

Source:

Similar Datasets

2011-05-11 | E-GEOD-25066 | biostudies-arrayexpress
2014-06-17 | MTBLS92 | MetaboLights
2011-05-11 | E-GEOD-25065 | biostudies-arrayexpress
2011-05-11 | E-GEOD-25055 | biostudies-arrayexpress
2015-01-21 | E-GEOD-48073 | biostudies-arrayexpress
2016-03-24 | E-GEOD-43816 | biostudies-arrayexpress
2024-08-27 | GSE270967 | GEO
2021-12-31 | GSE182951 | GEO
2015-01-21 | GSE48073 | GEO
2021-11-19 | GSE169455 | GEO